Crispr Therapeutics shares tumble after significant earnings miss
Brandon Lavertu, the Chief Financial Officer of ECB Bancorp , Inc. (NASDAQ:ECBK), recently made significant stock purchases, according to a filing with the Securities and Exchange Commission. On February 20 and 21, Lavertu acquired a total of 3,145 shares of ECB Bancorp’s common stock. The transactions were executed at prices ranging from $14.12 to $14.4809 per share, amounting to a total investment of approximately $44,879. The purchases come as the $129.62M market cap company trades near its 52-week high of $15.75, with InvestingPro analysis indicating the stock is currently overvalued.
These acquisitions were made through various personal accounts, including an IRA and a Roth IRA, reflecting Lavertu’s confidence in the company’s prospects. Following these transactions, Lavertu’s total direct and indirect holdings in ECB Bancorp have increased, showcasing his continued commitment to the financial institution. While the company maintains profitability and shows a 4% revenue growth over the last twelve months, InvestingPro data reveals several additional insights about the company’s financial health and growth prospects. Subscribers can access more than 30 key metrics and additional ProTips for deeper analysis.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.